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Abstract
Background: The aim of this proteomic study was to look for changes taking place in plasma proteomes of
patients with acute myocardial infarction (AMI), unstable angina pectoris (UAP), and stable angina pectoris (SAP).
Methods: Depleted plasma proteins were separated by 2D SDS-PAGE (pI 4-7), and proteomes were compared
using Progenesis SameSpots statistical software. Proteins were identified by nanoLC-MS/MS. Proteins were
quantified using commercial kits. Apolipoprotein A1 was studied using 1D and 2D SDS-PAGE, together with
western blotting.
Results: Reciprocal comparison revealed 46 unique, significantly different spots; proteins in 34 spots were
successfully identified and corresponded to 38 different proteins. Discrete comparisons of patient groups showed
45, 41, and 8 significantly different spots when AMI, UAP, and SAP were compared with the control group. On the
basis of our proteomic data, plasma levels of two of them, alpha-1 microglobulin and vitamin D-binding protein,
were determined. The data, however, failed to prove the proteins to be suitable markers or risk factors in the
studied groups. The plasma level and isoform representation of apolipoprotein A1 were also estimated. Using 1D
and 2D SDS-PAGE, together with western blotting, we observed extra high-molecular weight apolipoprotein A1
fractions presented only in the patient groups, indicating that the novel high-molecular weight isoforms of
apolipoprotein A1 may be potential new markers or possible risk factors of cardiovascular disease.
Conclusion: The reported data show plasma proteome changes in patients with AMI, UAP, and SAP. We propose
some apolipoprotein A1 fractions as a possible new disease-associated marker of cardiovascular disorders.
Introduction
Cardiovascular disease (CVD) is the major cause of pre-
mature death in Europe. It is an important cause of
decrease in quality of life, disability, and contributes
substantially to the escalating costs of health care [1].
Generally, the epidemic of CVD is a global phenom-
enon, and the magnitude of its increase in incidence has
potentially major implications for countries that repre-
sent much of the developed world. There are two major
approaches to the prevention of CVD: public health/
community-based strategies and clinical-based strategies
with a targeted approach to high-risk patients using
modern methods to estimate risk factors, plus various
combinations of these approaches. Thus, laboratory
medicine now plays a crucial role in identifying risk fac-
tors, early events, and conditions triggering plaque rup-
ture in coronary heart disease [2,3]. The greatest
progress in laboratory research has resulted in the dis-
covery of new and more-promising biochemical markers
of myocardial damage [4].
Nowadays modern scientific techniques like genomics,
proteomics, and metabolomics serve to discover new
therapeutic targets and biomarkers [5,6]. In this way
newly achieved insights into the mechanisms of cardio-
vascular disease can lead to proposals of new modern
therapies and to the improvement of CVD diagnostics
and therapy monitoring [7]. The importance of measur-
ing proteins as biomarkers has become increasingly
clear, as mRNA transcripts cannot be directly correlated
to protein expression [8]; and posttranslational
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human diseases, including CVD.
Although the cardiac myocytes are the best source
that might provide the possibility to observe proteome
changes in the failed heart tissue, plasma protein bio-
markers have been the focus of extensive study in recent
years [4,6,9,10]. Moreover, cardiac myocytes are not
usually available for diagnoses purposes; and blood col-
lection is a quick and simple procedure that is less inva-
sive and easily executable, with almost no patient
discomfort.
Proteomics offers a combination of different techni-
ques to analyze proteins in a sample at a given time
with the detection of protein levels, isoforms, posttran-
slational modifications, etc. The possibility of exploring
t h ec u r r e n ts t a t eo fo r g a n i s m, tissues, or other subpro-
teomes of interest (cells, plasma, etc.) is an essential
attribute of proteomics. Information obtained by com-
paring proteomic results between different groups or
under different conditions may be useful in general, as
well as at a personalized patient level [11].
T h ea i mo ft h i ss t u d yw a st oc o m p a r ep l a s m ap r o -
teomes of patients with acute myocardial infarction
(AMI), unstable angina pectoris (UAP), stable angina
pectoris (SAP), and control subjects to find any signifi-
cant protein differences within the groups of study, and
to search for potential new proteomic markers of CVD.
Methods
A total of 130 patient plasma samples were used in this
proteomic study. The samples were divided into four
individual groups: patients with acute myocardial infarc-
tion with ST elevations; patients with unstable angina
pectoris; patients with stable angina pectoris; and a con-
trol group of donors exhibiting a normal coronary
angiogram. Characteristics of the study groups are sum-
marized in Table 1.
All acute coronary syndrome patients were classified
according to criteria including chest pain, ECG changes
(ST elevation, non ST elevation) and troponin I positiv-
ity. All these patients underwent coronary angiography -
patients with ST elevation myocardial infarction imme-
diately in the regime of primary PCI, and patients with-
out ST elevations within 24 hours of admission with
PCI of culprit lesion.
All tested individuals agreed to participate in this
study, gave informed consent, and the study was
approved by the Ethics Committee of the Motol Univer-
sity Hospital. All samples were obtained and analyzed in
accordance with the Ethical Committee regulations of
the Institute of Hematology and Blood Transfusion. All
investigations conform to the Declaration of Helsinki.
Blood was collected by venipuncture into tubes coated
with EDTA within the 24-hour window with respect to
cardiac events. Plasma was obtained by the centrifuga-
tion (15 min, 3000 × g) of blood samples; and plasma
aliquots were then transferred to polypropylene Eppen-
dorf tubes and stored at -70°C until used.
Thawed plasma samples were centrifuged (5 min,
12000 × g), diluted 1:4 by depletion buffer (Agilent,
Santa Clara, CA, USA), and filtrated using 0.22 μm Spin
filters (Agilent) for 1 minute by centrifugation at 12000
× g. A MARS Hu-6 4.6 × 100 mm column (Agilent) was
used to remove six high-abundant proteins (albumin,
IgG, a1-antitrypsin, IgA, transferrin, and haptoglobin).
5K MWCO Spin Concentrators (Agilent) were used to
desalinate and concentrate the samples (3000 × g, 20°C).
MilliQ water (4 mL) was added to concentrated sam-
ples; and the desalinating-concentrating step was
repeated three times. Finally, desalinated and concen-
trated samples were vacuum dried, frozen rapidly, and
stored at -70°C.
1D electrophoresis was performed using 10 μLo fa n
undepleted plasma sample that was resuspended in 200
μL of reducing sample buffer (62.5 mM Tris, 4.05% w/v
SDS, 20% v/v glycerol, 10% v/v 2-mercaptoethanol, and
a trace of bromophenol blue). The sample was then
heated at 95°C for 3 min, centrifuged; and 10 μLo ft h e
Table 1 Characteristics of the study groups
AMI (n =
27)
UAP (n =
26)
SAP (n =
38)
Control (n =
39)
Age (years ±
SEM)
65 ± 14 72 ± 12 66 ± 10 67 ± 12
Males n (%) 16 (59) 18 (69) 28 (74) 14 (36)
Hypertension n
(%)
12 (44) 23 (88) 34 (89) 28 (72)
Dyslipidemia n
(%)
14 (52) 16 (62) 32 (84) 26 (67)
Diabetes n (%) 6 (22) 7 (27) 15 (39) 8 (21)
Smoking n (%) 13 (48) 5 (19) 7 (18) 4 (10)
History of MI n 2 5 12 2
History of
stroke n
044 1
BMI 28.3 ± 3.3 27.9 ± 4.3 28.7 ± 5.3 27.5 ± 4.4
creatinine
(μmol/L)
87.7 ± 31.6 88.5 ± 26.5 87.5 ± 26.9 75.3 ± 17.6
treatment n
(%):
Aspirin 5 (19) 14 (54) 26 (68) 20 (51)
ADP blockers 1 (4) 6 (23) 12 (32) 6 (15)
Beta blockers 4 (15) 10 (39) 25 (66) 20 (51)
ACE inhibitors 2 (7) 16 (62) 22 (58) 12 (31)
ARB 2 (7) 1 (4) 5 (13) 8 (21)
Statins 2 (7) 11 (42) 28 (74) 20 (51)
Ca blockers 1 (4) 5 (19) 11 (29) 6 (15)
Warfarin 2 (7) 2 (8) 4 (11) 2 (5)
AMI acute myocardial infarction, SAP stable angina pectoris, UAP unstable
angina pectoris, smoking reflects current smokers, body-mass index (BMI) and
serum creatinine are expressed as average values ± standard deviation
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SDS-PAGE (8 × 10 cm, 10% gradient gel, 3.75% stacking
gel, 5°C, 30 mA/gel) using a P8SD vertical electrophor-
esis separation system (Owl; Thermo Scientific, Wal-
tham, MA, USA).
2D SDS-PAGE, image analysis, protein digestion, and
mass spectrometry analysis were performed as described
before [12]. Briefly, isoelectric focusing (IPG strips pI 4-
7, 7.7 cm) and SDS-PAGE (conditions as used in 1D
SDS-PAGE) were used in the first and in the second
dimension, respectively. Gels were stained with colloidal
Coomassie blue, scanned, and processed with Progenesis
SameSpots software (Nonlinear Dynamics, Newcastle
u p o nT y n e ,U K ) .A l lf o u rg r o u p s( A M I ,U A P ,S A P ,a n d
normal control group - N) were compared with each
other; and fold values, as well as p-values of all spots,
were computed with the above mentioned software,
using one way ANOVA analysis. Moreover, separate
comparisons of each patient group relative to the con-
trol group were created. PCA (Principal Component
Analysis) of the compared groups was performed by the
SameSpot software, using the spots of statistical signifi-
cance. Protein identification was then only conducted
on spots that significantly differed. The selected spots
were excised from the gel, and proteins were in-gel
digested by trypsin. An HCT ultra ion-trap mass spec-
trometer (Bruker Daltonics, Bremen, Germany) with
nanoelectrospray ionization, coupled to a UltiMate 3000
nanoLC system (Dionex, Sunnyvale, CA, USA) was used
to perform MS analysis. MASCOT (Matrix Science,
London, UK) was used for database searching (SWISS-
PROT release 2010_12). Two unique peptides (fulfilling
a minimal Mascot score) were necessary to successfully
identify a protein.
Western blotting was performed using an Owl HEP-1
Semi Dry Electroblotting System (Thermo Scientific).
Proteins were transferred from gel to a PVDF mem-
brane (10 V constant voltage for 1 hr); the membrane
was then incubated with a blocking buffer (3% BSA in
PBS) at 4°C overnight, rinsed; and incubated with goat
anti-Apolipoprotein A1 horseradish peroxidase conju-
gated antibody (Baria, Psary, Czech Republic), 1:10000
dilution, at 37°C for 30 min. After rinsing, a chemilumi-
nescent substrate (SuperSignal West Pico; Thermo
Scientific) was added to the membrane for 5 min; and a
2 hr film exposition (Amersham Hyperfilm ECL; GE
Life Sciences, Piscataway, NJ, US) was performed. After
which, the film was developed and scanned.
Apolipoprotein A1 (apoA1), alpha-1 microglobulin
(a1m), and vitamin D-binding protein (VDBP) plasma
levels were measured using kits (ApoA1 assay KAI-002
and Apo A1/B calibrator KAI-008C, Alpha-1 Microglo-
bulin assay KAI-056 and KAI-068C calibrator, and Vita-
min D Binding Protein ELISA KT-515; all kits were
purchased from Kamiya Biomedical, Seattle, WA, USA)
according to manufacturer instructions. ApoA1 and
a1m were measured in triplet, VDBP in duplicate.
Results were expressed as means ± standard deviations.
One-way ANOVA was used to determine the statistical
significance of plasma level changes of apoA1 and a1m
in samples, while an unpaired t-test was used for the
comparison of VDBP when the AMI group was com-
pared with the control group.
Results
2D gels were prepared for the experiments, and scanned
gel images were divided into four individual groups
according to patient group disposal: acute myocardial
infarction (AMI, n = 27), unstable angina pectoris (UAP,
n = 26) stable angina pectoris (SAP, n = 38), and normal
c o n t r o l( N ,n=3 9 ) .A l lf o u rg r o u p sw e r ec o m p a r e d
together, with a separate comparison of individual
groups relative to the control group.
Reciprocal comparison of all four groups revealed 46
unique spots that significantly (p < 0.05) differed in nor-
malized volumes (Figure 1); the proteins in 34 of the 46
spots were successfully identified by mass spectrometry.
These 34 identified spots correspond to 38 different
proteins. The list of spots, including protein identifica-
tion, sequence coverage (%), protein accession number,
fold value, ANOVA p-value, and logarithms of spot nor-
malized volume (LSNV) with its standard deviation for
each group, is summarized in (Additional file 1: Table
S1). The fold value shows the fold difference between
the groups with the lowest and highest normalized
volumes.
Separately comparing the three patient groups with
the control group we found: 45 significantly differing
Figure 1 Positions of significantly differed spots on a 2D gel.
Positions of all spots that were found to significantly differ in 2D
gels of reciprocal comparison of all four groups and separate
comparisons of the three patient groups with the control group.
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which were successfully identified and corresponded to
38 different proteins; 41 significantly differing spots
when comparing UAP with N (Figure 1), 38 of which
were successfully identified and corresponded to 23 dif-
ferent proteins; 8 significantly differing spots when com-
paring SAP with N (Figure 1), 5 of which were
successfully identified and corresponded to 9 different
proteins. The lists of spots, including protein identifica-
tion, sequence coverage (%), protein accession number,
fold value, and ANOVA p-value, are summarized in
(Additional file 2: Table S2). The fold value shows the
fold difference of distinct groups relative to the control
group.
PCA of the mutual comparison of all four groups indi-
cated the distinct separation of AMI, UAP, and a third
aggregate that contained SAP and the control group
(Figure 2). According to the Principle Component 1,
there are two aggregates: the first composed of acute
coronary syndrome groups (AMI and UAP) and the sec-
ond containing SAP and the control group. When the
Principle Component 2 is taken into account, it is
apparent that the acute coronary syndrome group is
separated into two discrete groups (AMI and UAP) (Fig-
ure 2).
Plasma levels of three different proteins (apolipopro-
tein A1, alpha-1 microglobulin, and vitamin D-binding
protein) were quantified. Plasma concentrations of
apoA1 (mg/dL) were determined in each respective
group: 124.1 ± 17.3 (AMI, n = 28); 118.0 ± 23.0 (UAP,
n = 28); 132.5 ± 28.0 (SAP, n = 27); and 147.2 ± 28.2
(N, n = 34). The statistical analysis showed a significant
difference between the groups (ANOVA p = 0.000055).
Plasma concentrations of a1m (mg/L) were determined
as follows: 25.0 ± 6.0 (AMI, n = 36); 24.9 ± 6.5 (UAP, n
= 34); 26.8 ± 7.5 (SAP, n = 40); and 22.2 ± 5.9 (N, n =
37). A significant difference between the groups
(ANOVA p = 0.0369) was also observed. VDBP plasma
concentration (ug/mL) was determined in control and
AMI groups: 327.0 ± 52.4 (AMI, n = 20) and 327.3 ±
52.0 (N, n = 20). No significant difference was observed
between these two groups.
Western blot analysis of 1D gels (20 samples of each
group) was performed to observe apoA1 fractions. In all
patient group samples (AMI, UAP, SAP) extra fractions
of higher molecular weight (MW) were observed (in
addition to the regular apoA1 fraction); whereas no
such extra fractions were observed in the control group
(Figure 3). 2D western blot analysis was then performed,
and several extra spots (with MW corresponding to
those of 1D extra apoA1 bands) were observed. Protein
identification confirmed the presence of apoA1 only in
one fourth of all identified samples.
Discussion
Many of the identified proteins are known markers, risk
factors, or proteins known to be involved in cardiovas-
cular disease; e.g. transthyretin, apoA1, fibrinogen,
serum amyloid A protein, haptoglobin, plasminogen,
and others [2,6]. Our study presents both a comparison
of the respective patient groups with a control group,
and the mutual comparison of all groups together; and
thus offers deeper insight into proteome changes. As an
example, spot 26 (fibrinogen alpha and beta chains) sig-
nificantly differed in AMI vs. N and UAP vs. N, whereas
no significant differencew a sf o u n di nS A Pv s .N .T h e
results obtained from the mutual group comparison
show that the LSNV value of spot 26 is also increased
in SAP (with an approximate 50% increase when
Figure 2 Principal Component Analysis (PCA) of all compared
groups. PCA shows separation into three aggregates using the first
two principal components. Acute coronary syndrome group
composed of AMI (pink) and UAP (blue) is distinguishable according
to the Principle Component 1. According to the Principle
Component 2 the three PCA resolved groups of samples are
composed of mutually resolved AMI and UAP samples, and of a
group comprising SAP (violet) and control samples (yellow).
Figure 3 Apolipoprotein A1 isoforms pattern. Representation of
apolipoprotein A1 (apoA1) regular band (1) and extra high MW
fraction (2) in all four groups (N - control group, AMI - acute
myocardial infarction, UAP - unstable angina pectoris, and SAP -
stable angina pectoris) using 1D and 2D western blotting.
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observed in acute coronary syndrome (AMI and UAP)
are non-significantly present in SAP. Fibrinogen chains
are known to be involved in cardiovascular disease
(gamma chain variants associate with increased throm-
botic risk; alpha and beta chains have been found to be
modified; etc.) [13,14].
We have also found several new possible protein bio-
marker candidates: lumican, protein AMBP, VDBP, and
biotinidase. They have not been previously associated
with CVD; or their role in CVD is not known. On the
basis of our data, we further focused on two proteins,
quantifiable with commercially available immunodetec-
tion kits, to estimate their plasma levels and thus to
consider their roles as possible biomarkers - VDBP and
protein AMBP. In apoA1, a known marker of CVD, we
assessed its plasma levels, including proportional repre-
sentation of isoforms.
Vitamin D-binding protein is a multifunctional pro-
tein, which carries vitamin D sterols, associates with
membrane-bound immunoglobulin on the surface of B-
lymphocytes, prevents the polymeratization of actin by
binding actin monomers, etc. As a part of the actin
scavenging system, VDBP binds actin released from cells
upon injury; wherein these complexes are then rapidly
cleared from the bloodstream [15]. It is assumed that
the influence of VDBP prevents the harmful effects of
actin filaments in blood vessels. VDBP is also considered
to be a regulator of the inhibitory effect of acetylsalicylic
acid on platelets [16]. We observed VDBP spot change
within acute coronary syndrome groups (AMI and UAP)
exclusively in the AMI group; therefore VDBP plasma
level in AMI was compared with the control group. We
did not, however, observe any significant VDBP level
difference within these groups. So, the observed spot
change might be caused either by posttranslational mod-
ification of VDBP in the AMI group or by other co-
identified proteins in the spot.
Protein AMBP is a complex glycoprotein secreted in
plasma. Its precursor is proteolytically processed into
distinct functioning proteins: alpha-1-microglobulin
(a1m), a low molecular weight plasma glycoprotein, and
an inter-alpha-trypsin inhibitor light chain (bikunin)
that is further cleaved to trypstatin [17]. All protein
AMBP peptides identified by mass spectrometry were
part of the a1m sequence (peptides: 44-57, 63-85, 167-
185, and 186-202; the amino acid sequence of protein
AMBP). Moreover, molecular mass estimated by SDS-
PAGE corresponded to a1m. The function and physiolo-
gical role of a1m is not fully understood; nevertheless,
this protein presumably plays a role in the regulation of
the immune system, and is involved in defending tissue
against oxidation by reactive oxygen species and heme
[18]. A1m is known to be complexed to macromolecules
(immunoglobulin A, albumin, and prothrombin), as well
as to be present in a free form of a monomeric protein
[18]. This protein is considered to be a marker of renal
insufficiency, and to reflect the overall inflammatory sta-
tus in patients with arterial hypertension and normal
renal function [19]. We found that spot 18 (protein
AMBP) differed significantly when mutually comparing
all four groups. LSNV values of this spot were decreased
in all three patient groups with the lowest value in UAP.
The comparison of individual groups with the control
group showed another significant LSNV decrease (UAP
vs. N, spot 18, p = 0.002) and showed a difference in
spot 50 (AMI vs. N) with non-unique protein identifica-
tion. We quantified a1m plasma levels within all four
groups to compare them with the results obtained by
2D-electrophoresis. We found significant differences of
a1m plasma concentrations; nevertheless, the results did
not correspond to those observed by 2D-electrophoresis.
This is probably caused by posttranslational modifica-
tion (UAP vs. N, spot 18) or by the presence of other
proteins in spot 50 (AMI vs. N), as in the case of the
VDBP described above. Summarizing our results, a1m
does not seem to be a suitable marker or even a risk
factor of cardiovascular diseases.
ApoA1 participates in the transport of cholesterol
(between tissues and the liver) by promoting cholesterol
efflux and by acting as a cofactor for the lecithin choles-
terol acyltransferase. This protein is known to be a use-
ful tool in the assessment of coronary heart disease risk.
High levels of apoA1 can help to prevent heart disease,
and it has also been shown that apoA1 plasma level is
decreased in cardiovascular disease [2]. Further, it has
been demonstrated that several apoA1 isoforms are pre-
sent in plasma, and that at least some of these isoforms
probably change during acute coronary syndrome [20].
Our 2D SDS-PAGE results showed significant changes
in apoA1 LSNV values (all patient groups vs. N, AMI
vs. N, UAP vs. N), as well as changes of several isoforms
(spots 61-69, UAP vs. N). We quantified apoA1 plasma
levels in all four groups to assess whether the changes
are based on apoA1 isoforms (thus confirming the role
of posttranslational modifications) or on a total concen-
tration. ApoA1 plasma levels were significantly
decreased as compared with the control in all three
patient groups, with the minimum in UAP in agreement
with previous literature [21-23]. The majority of apoA1
changes obtained by 2D SDS-PAGE were observed in
UAP vs. N (10 spots, 9 of them unique identification).
This is consistent with the highest concentration differ-
ence (UAP vs. N) obtained by apoA1 quantification. If
apoA1 changes were based on plasma concentration
only, the values of both differences (in plasma concen-
tration and that observed in 2D electrophoresis) should
be the same. ApoA1 plasma level change in UAP vs. N
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forms LSNV changes (spots 61-69) range from 20% to
80%. This indicates that apoA1 changes in UAP are
based not only on plasma concentration differences, but
also on posttranslational changes of apoA1 isoforms.
We performed western blotting with immunodetection
to observe all spots in 2D SDS-PAGE, which could con-
tain apoA1 to test the possibility of the influence of
non-identified apoA1 spots to the results. The spots
observed by immunodetection matched those observed
in 2D SDS-PAGE in which apoA1 was identified. Sur-
prisingly, we also detected a region with a group of sev-
eral apoA1 spots of higher molecular weight
(approximately 50 kDa) than that of apoA1 (28 kDa).
B a s e do nt h i sf i n d i n g ,1 DS D S - P A G Eo f2 0s a m p l e so f
each group (AMI, UAP, SAP, and N) followed by immu-
noblotting, was performed to estimate the possible pre-
sence of the high MW apoA1 fractions in other groups.
Two different extra bands with detected apoA1 were
observed (in addition to the regular apoA1 bands) in all
samples of all patient groups (AMI, UAP, and SAP),
while no extra bands were detected in the samples of
the control group (Figure 3). Despite the low number of
replicates (n = 20, each group) and the observed varia-
bility of band intensities, we assume that the high MW
apoA1 fraction might be a new disease-associated mar-
ker of cardiovascular disorders. The non-significant
change of this fraction in 2D SDS-PAGE analysis might
be caused by a low concentration not detectable by 2D
electrophoresis, or by overlapping with more abundant
proteins in spots. Finally, several 2D gels, as well as 2D
western blots, were prepared to estimate the pattern of
the high MW apoA1 fraction spots, and to identify the
extra apoA1 fraction by mass spectrometry. The spot
pattern in 2D gels was extremely variable as expected,
and corresponded to bands observed in the 1D gels. We
assume that either apoA1 is covalently linked (due to
the denaturing conditions of SDS-PAGE) to another
protein, or that apoA1 fragments are linked to a protein
or proteins. Unfortunately, mass spectrometry analysis
did not reveal the composition of the extra apoA1 frac-
tion, with only a quarter of all identified samples con-
taining apoA1. This might be caused by the presence of
high-abundant proteins that overlap the spots as
observed by western blotting. The presence of apoA1
fragments instead of the intact protein molecule could
be another explanation. It has been shown that there
are apoa1 fragments present in the plasma of patients
with nephrotic syndrome [24].
The Principal Component Analysis applied to the data
obtained within all four groups of samples showed their
separation into three rather well resolved aggregates
using the first two principal components (Figure 2).
CVD patients in this study can be stratified by tradi-
tional clinical diagnoses into acute syndrome groups
(AMI together with UAP) and into SAP. This stratifica-
tion (one acute coronary syndrome group composed of
AMI and UAP) is clearly distinguishable according to
the Principle Component 1. According to the Principle
Component 2, the three well-resolved PCA groups of
samples are composed of mutually resolved AMI and
UAP samples and of a group comprising SAP and con-
trol samples. The SAP and control samples are poorly
distinguished mutually, using a given relatively small set
of proteins for PCA, as compared with the normal
healthy population without atherosclerosis. This may be
d u et oc o m p a r a b l ea g ea n dt h ec o m m o np r e s e n c eo f
risk factors in both SAP and control patients. The
obtained results of the PCA method are thus in agree-
ment with the stratification of patients using classical
clinical diagnostics.
The role of new markers is not only to distinguish the
studied groups. The knowledge of protein markers and
changes in their concentration and/or posttranslation
modification should increase our understanding of the
mechanisms that are involved in coronary disease, may
constitute new potential risk factors and help to predict
personal risk and thus help in the treatment. The cur-
rent markers (troponin etc.) are sufficient to help or
predict diagnosis and distinguish the groups used in this
study. However, the role of novel apoA1 isoforms as a
new risk factor should be further investigated. It is not
known at present whether the apoA1 isoforms are in
patients’ plasma as a result or the cause of the patient’s
disease. Moreover, it is hard to speculate on the role
and possible involvement of apoA1 isoforms in cardio-
vascular diseases: to date neither the composition of
these isoforms, nor the influence of other factors (age,
treatment, smoking, etc.) on the level and composition
of these isoforms is known.
Conclusion
T h er e p o r t e dd a t as h o wp l a s m ap r o t e o m ec h a n g e si n
patients with acute myocardial infarction, unstable
angina pectoris, and stable angina pectoris. Proteins that
are known markers or risk factors of CVD were
observed, as well as new possible marker candidates. On
the basis of our data, we tested two of the candidates,
vitamin D-binding protein and alpha-1 microglobulin, as
potential CVD markers. The estimation of their plasma
levels, however, did not indicate them as suitable CVD
markers. The testing of the known CVD marker, apoA1,
r e v e a l e dt h ep o s s i b l er o l eo fb i o m a r k e ri s o f o r m sa n d
their posttranslational modifications. Therefore, we pro-
pose the high MW apoA1 fraction as a possible new dis-
ease-associated marker of cardiovascular disorders.
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